Heron rises as preliminary revenue figures exceed estimates

Heron Therapeutics (HRTX) stock jumps as the company's unaudited Q4 and 2025 revenue figures beat forecasts, driven by its ...

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced ...
American Association of Individual Investors

Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 10.63%

As of Friday, January 09, Heron Therapeutics, Inc.’s HRTX share price has surged by 10.63%, which has investors questioning ...
TMCnet

Heron Finance expands alternative investments platform, launching new private infrastructure investing strategy

The new private infrastructure strategy expands Heron's alternative investments platform beyond private credit and private ...

Heron Therapeutics Rises on Expected 4Q, FY25 Revenue Beat

Heron Therapeutics shares rose after the company said it expects to report revenue for the fourth quarter and full year above analysts' expectations. Shares were recently up 16% to $1.47. The stock is ...
FiercePharma

Heron's opioid alternative Zynrelef, slated for blockbuster status, hits a rough Q4 as Jefferies seek 'launch clarity'

Heron Therapeutics' new drug Zynrelef, an opioid alternative for postoperative pain, has been slated by Evercore analysts to be a potential blockbuster, but its early launch is hitting turbulence. The ...
Investing.com Australia

Heron Therapeutics stock soars after strong Q4 revenue growth

Investing.com -- Heron Therapeutics (NASDAQ:HRTX) stock surged 17% following the company’s announcement of preliminary, unaudited fourth quarter and full-year 2025 financial results, with ZYNRELEF ...